Which company develops and produces Capmatinib?

Capmatinib is a drug developed and produced by Novartis (Novartis Pharmaceuticals).

Novartis is a leading global pharmaceutical company dedicated to developing and producing innovative medicines and providing medical solutions to patients around the world. Capmatinib is a tyrosine kinase inhibitor (TKI) developed by the company and is used to treat patients with non-small cell lung cancer (NSCLC) carrying METexon 14 skipping mutations.

The mechanism of action of capmatinib is to inhibit the activity ofMETkinase and interfere with the conduction of abnormal signaling pathways, thereby preventing the proliferation and spread of cancer cells. Clinical trial results show that capmatinib shows a certain degree of therapeutic effect in NSCLC patients carrying MET exon 14 skipping mutations, providing a new option for the treatment of this specific subgroup of patients.

However, like all medications, capmatinib may cause some side effects. Common adverse reactions may include fatigue, nausea, vomiting, diarrhea, rash, etc. Therefore, before using capmatinib, doctors will evaluate a patient's overall health and weigh the risks and benefits of treatment on an individual basis.

As a prescription drug, capmatinib needs to be used under a doctor's supervision and in accordance with the doctor's medication recommendations and dosage instructions. Patients should report any discomfort or adverse reactions to their doctor immediately.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.